Home ›
Hepatocellular Carcinoma (HCC) Liver Cancer Trials ›
NCT06689540
Mts105 for Advanced Hepatocellular Carcinoma
This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.
Trial Details
NCT ID NCT06689540
Phase PHASE1
Sponsor Shen Lin
Status RECRUITING
Cancer Type Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
Locations (sample) Beijing, China|39.9075,116.39723
Key Eligibility Criteria
Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as … Positive for GPC3 expression per immunohistochemical (IHC) staining. Failure of standard systemic therapies, including at least one immune checkpoint inhibitor and one targeted therapy (Tyrosine Kinase Inhibitors, an… Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).
For full eligibility, visit ClinicalTrials.gov .